India's Sun Pharmaceutical has signed an agreement to acquire US biotech Concert Pharmaceuticals and its lead drug deuroxilitinib, in phase 3 testing for alopecia areata, a leading cause of
German pharma group Bayer has made another play in the digital medical imaging category, buying Blackford Analysis and its artificial intelligence-based platform for radiological assessment
Angion Biomedica ended 2022 in the midst of a strategic review after its lead drug for kidney diseases flamed out, and it has now charted a path forward – a reverse merger with clinical-sta
mRNA specialist BioNTech has driven its partnership with UK artificial intelligence InstaDeep into top gear, agreeing to buy the company outright in a cash and equity deal that values it at
French drugmaker Ipsen has continued a recent spate of deal-making with a $42-per-share offer to buy US biotech Albireo and its rare disease therapy Bylvay.
GSK looks like it is starting to show the benefit of a revamp of its business under chief executive Emma Walmsley, with recent product launches driving a 10% rise in sales
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.